

lymphoma affects various organs, such as skin, gastrointestinal (GI) tract, liver, spleen, and bone marrow. Symptoms include enlarged lymph nodes of the neck. Most NK/T cell lymphoma subtypes are driven by Epstein bar viral infections.

[0006] Current treatments include chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone), followed by stem cell transplant; but progression-free survival remains at 40-50%. Current treatments under investigation include Alemtuzumab, Carfilzomib (proteasome inhibitor), Romidepsin (HDAC inhibitor), Bevacizumab, Brentuximab vedotin (antibody-drug conjugate), Bortezomib (proteasome inhibitor), Belinostat (HDAC inhibitor), Pralatrexate, Vorinostat (HDAC inhibitor), and Avelumab. Despite the variety of drugs in development, many of them are often used off-label and have yielded mixed results.

[0007] There are currently no effective therapies for the treatment of NK/T cell lymphoma, and no therapy that selectively targets NK/T cell lymphoma has been developed. Current therapies for NK/T cell lymphoma may have off-target effects and are not entirely effective. The high disease mortality combined with the lack of effective treatments emphasize the need for therapeutic advancements in NK/T cell lymphoma.

[0008] Accordingly, there is a need in the art to develop safe and effective therapies for treating diseases mediated by NK cells and/or T cells that express CD94, such as NK/T cell lymphoma.

SUMMARY-OF-THE-DISCLOSURE

[0009] To meet these and other needs, the present disclosure provides, *inter alia*, antibodies that bind specifically to CD94 (*e.g.*, human CD94), methods of treating diseases or injuries associated with NK cells and/or T cells that express CD94, *e.g.*, NK/T cell lymphomas and leukemias (*e.g.*, LGL leukemia), and methods of depleting or reducing the numbers of NK cells and/or T cells that express CD94 in a subject upon administration of an antibody that specifically binds to CD94. These antibodies of the present disclosure may have one or more of the following characteristics: high affinity binding to human CD94 (*e.g.*, cells expressing human CD94 on their surface), cross-reactivity to cynomolgus monkey CD94 (useful for preclinical studies), ability to bind human CD94 without blocking its interaction with HLA-E, minimal internalization following binding to CD94, and/or induction of ADCC against cells expressing CD94, such as leukemic cells. These characteristics are thought to be advantageous, *e.g.*, for testing, development, and use in treating NK/T cell-based diseases, such as lymphomas and leukemias. For example, without wishing to be bound to theory, it is thought that targeting CD94 on NK cells for ADCC may induce cancer cells (*e.g.*, LGL leukemic or lymphoma cells) to kill other cancer cells.

[0010] In one aspect, the present disclosure refers to a human or humanized antibody that binds to human CD94, wherein: (a) binding of the antibody to human CD94 does not block binding between human CD94 and human HLA-E; and/or (b) the antibody binds to human CD94 and cynomolgus CD94. In some aspectexamples, provided herein are human or humanized antibodies that bind to human CD94, wherein binding of the antibody to human CD94 does not block binding between human CD94 and human HLA-E. In some embodimentexamples, the antibody binds human CD94 expressed on the surface of a cell (*e.g.*, a human natural killer (NK) cell). In some embodimentexamples, the antibody binds an extracellular domain of human CD94. In some embodimentexamples, the antibody binds cynomolgus CD94 expressed on the surface of a cell. In some embodimentexamples, binding of the antibody to cells expressing human CD94 blocks less than

20% of HLA-E binding to the human CD94. In other [aspectexamples](#), provided herein are human or humanized antibodies that bind to human CD94 and cynomolgus CD94 (*e.g.*, that are capable of binding to human CD94 and cynomolgus CD94 separately). In some [embodimentexamples](#), the antibody binds human CD94 expressed on the surface of a cell (*e.g.*, a human natural killer (NK) cell). In some [embodimentexamples](#), the antibody binds cynomolgus CD94 expressed on the surface of a cell (*e.g.*, a cynomolgus NK cell, or a cell such as a human cell that overexpresses cynomolgus CD94). In some [embodimentexamples](#), binding of the antibody to human CD94 does not block binding between human CD94 and human HLA-E. In some [embodimentexamples](#), incubating the antibody with a cell expressing human CD94 on its surface for 24 hours at 37°C results in a decrease in surface antibody staining of less than 50% due to internalization.

[0011] In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:2, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:3; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:4, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:5, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:6. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:6. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:19, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:20. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO:19, and the VL domain comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO:20. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO:19, and the VL domain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO:20. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:19, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:20. In some [embodimentexamples](#), the VH domain comprises the amino acid sequence of SEQ ID NO:19, and the VL domain comprises the

amino acid sequence of SEQ ID NO:20. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:12. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:12. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:21, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:22. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO:21, and the VL domain comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO:22. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21, and the VL domain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO:22. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:21, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:22. In some [embodimentexamples](#), the VH domain comprises the amino acid sequence of SEQ ID NO:21, and the VL domain comprises the amino acid sequence of SEQ ID NO:22. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID

NO:17, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:18. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:18. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:23, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:24. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO:23, and the VL domain comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO:24. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO:23, and the VL domain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO:24. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:23, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:24. In some [embodimentexamples](#), the VH domain comprises the amino acid sequence of SEQ ID NO:23, and the VL domain comprises the amino acid sequence of SEQ ID NO:24. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:30, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:31, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:35; (b) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:37, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:38; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID

sequence of SEQ ID NO:58, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:59; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:60, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61; (h) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:83, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:84, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:86, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61; or (i) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:64. In some embodiment examples, the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:88, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:89; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:90, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:35; (b) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:92, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:93; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence

amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:101, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:102, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:103; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:104, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61; (h) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:105, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:106, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:107; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:108, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61; or (i) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:109, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:110, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:111; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:112, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:113, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:64. In some embodiment examples, the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:30, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:31, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (b) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:37, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:38; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (c) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:39, and a CDR-H3 comprising the amino acid

sequence of SEQ ID NO:40; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (d) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:41, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:42, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:43; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:44, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:46; (e) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:49; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:51, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:52; (f) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:53, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:54, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:55; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:56; (g) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:57, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:58, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:59; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; (h) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:83, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:84, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:86, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; or (i) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:64. In some embodiment examples, the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:88, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:89; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (b) the VH domain comprises a CDR-

sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO:81, and the VL domain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO:82. In some [embodiment examples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:65, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:66; (b) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:67, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:68; (c) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:69, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:70; (d) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:71, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:72; (e) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:73, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:74; (f) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:75, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:76; (g) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:77, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:78; (h) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:79, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:80; or (i) the VH domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:81, and the VL domain comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO:82. In some [embodiment examples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises the amino acid sequence of SEQ ID NO:65, and the VL domain comprises the amino acid sequence of SEQ ID NO:66; (b) the VH domain comprises the amino acid sequence of SEQ ID NO:67, and the VL domain comprises the amino acid sequence of SEQ ID NO:68; (c) the VH domain comprises the amino acid sequence of SEQ ID NO:69, and the VL domain comprises the amino acid sequence of SEQ ID NO:70; (d) the VH domain comprises the amino acid sequence of SEQ ID NO:71, and the VL domain comprises the amino acid sequence of SEQ ID NO:72; (e) the VH domain comprises the amino acid sequence of SEQ ID NO:73, and the VL domain comprises the amino acid sequence of SEQ ID NO:74; (f) the VH domain comprises the amino acid sequence of SEQ ID NO:75, and the VL domain comprises

the amino acid sequence of SEQ ID NO:76; (g) the VH domain comprises the amino acid sequence of SEQ ID NO:77, and the VL domain comprises the amino acid sequence of SEQ ID NO:78; (h) the VH domain comprises the amino acid sequence of SEQ ID NO:79, and the VL domain comprises the amino acid sequence of SEQ ID NO:80; or (i) the VH domain comprises the amino acid sequence of SEQ ID NO:81, and the VL domain comprises the amino acid sequence of SEQ ID NO:82.

[0012] In some [aspectexamples](#), provided herein are antibodies that bind to human CD94. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:2, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:3; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:4, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:5, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:6. In some [embodimentexamples](#), the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:6. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:19, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:20. In some [embodimentexamples](#), the VH domain comprises the amino acid sequence of SEQ ID NO:19, and the VL domain comprises the amino acid sequence of SEQ ID NO:20. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:12. In some [embodimentexamples](#), the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR-

L1 comprising the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:12. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:21, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:22. In some [embodimentexamples](#), the VH domain comprises the amino acid sequence of SEQ ID NO:21, and the VL domain comprises the amino acid sequence of SEQ ID NO:22. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:17, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:18. In some [embodimentexamples](#), the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:18. In some [embodimentexamples](#), the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:23, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:24. In some [embodimentexamples](#), the antibody is a human antibody.

[0013] In some [aspectexample](#), provided herein are antibodies that bind to human CD94. In some [embodimentexamples](#), the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:30, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:31, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the

wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (c) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:39, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:40; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (d) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:41, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:42, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:43; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:44, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:46; (e) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:49; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:51, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:52; (f) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:53, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:54, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:55; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:56; (g) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:57, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:58, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:59; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; (h) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:83, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:84, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:86, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; or (i) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:64. In some ~~embodiment~~examples, the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 comprising an amino acid

comprises the amino acid sequence of SEQ ID NO:76; (g) the VH domain comprises the amino acid sequence of SEQ ID NO:77, and the VL domain comprises the amino acid sequence of SEQ ID NO:78; (h) the VH domain comprises the amino acid sequence of SEQ ID NO:79, and the VL domain comprises the amino acid sequence of SEQ ID NO:80; or (i) the VH domain comprises the amino acid sequence of SEQ ID NO:81, and the VL domain comprises the amino acid sequence of SEQ ID NO:82.

[0014] In further aspectexamples, provided herein are antibodies that bind the same epitope as an antibody according to any one of the above embodimentexamples. In one aspect, the present disclosure refers to an antibody that binds the same epitope as the antibody as disclosed herein. In some embodimentexamples, the antibodies of the present disclosure bind the same epitope as a reference antibody. In some embodimentexamples, the reference antibody comprises a VH domain comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and a VL domain comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:6. In some embodimentexamples, the reference antibody comprises a VH domain comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:9; and a VL domain comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:12. In some embodimentexamples, the reference antibody comprises a VH domain comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:15; and a VL domain comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:18. In some embodimentexamples, the reference antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:30, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:31, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (b) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:37, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:38; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (c) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:39, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:40; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid

sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (d) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:41, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:42, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:43; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:44, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:46; (e) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:49; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:51, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:52; (f) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:53, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:54, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:55; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:56; (g) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:57, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:58, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:59; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; (h) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:83, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:84, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:86, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; or (i) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:64.

[0015] In further [aspectexamples](#), provided herein are antibodies that compete with an antibody according to any one of the above [embodimentexamples](#) for binding to human CD94. In one aspect, the present disclosure refers to an antibody that competes with the antibody as disclosed herein for binding to human CD94. In some [embodimentexamples](#), the antibodies of the present disclosure compete for binding to human CD94 with a reference antibody. In some [embodimentexamples](#), the reference antibody comprises a VH domain comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and a VL domain comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:6. In some

embodimentexamples, the reference antibody comprises a VH domain comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:9; and a VL domain comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:12. In some embodimentexamples, the reference antibody comprises a VH domain comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:15; and a VL domain comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:18. In some embodimentexamples, the reference antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein: (a) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:30, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:31, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (b) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:37, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:38; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (c) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:39, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:40; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35; (d) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:41, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:42, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:43; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:44, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:46; (e) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:49; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:51, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:52; (f) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:53, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:54, and a CDR-H3 comprising the amino acid

sequence of SEQ ID NO:55; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:56; (g) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:57, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:58, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:59; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; (h) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:83, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:84, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:86, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; or (i) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:64.

[0016] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the antibody is an antigen-binding antibody fragment or single chain antibody. In some [embodimentexamples](#), the antibody further comprises an Fc region, *e.g.*, a human IgG1 Fc region. In some [embodimentexamples](#), the antibody comprises a human Fc region that is non-fucosylated. In some [embodimentexamples](#), the antibody is produced in a cell line (*e.g.*, a CHO cell line) deficient in an alpha-1,6-fucosyltransferase gene, such as FUT8. In some [embodimentexamples](#), the antibody binds to a human cellular Fc gamma receptor IIIA to a greater extent than an antibody comprising a wild type human IgG1 Fc region. In some [embodimentexamples](#), the antibody is capable of inducing antibody-dependent cellular cytotoxicity (ADCC) against a cell expressing human CD94 on its surface.

[0017] In further [aspectexamples](#), provided herein are polynucleotide(s) encoding the antibody according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to a polynucleotide encoding the antibody as disclosed herein. Further provided herein are vectors (*e.g.*, expression vectors) comprising the polynucleotide(s) according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to an expression vector comprising the polynucleotide as disclosed herein. Further provided herein are host cells (*e.g.*, isolated host cells or cell lines) comprising the polynucleotide(s) or vectors according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to an isolated host cell comprising the polynucleotide as disclosed herein or the vector as disclosed herein. Further provided herein are methods for producing an antibody, comprising culturing the host cell according to any one of the above [embodimentexamples](#) under conditions suitable for production of the antibody. In one aspect, the present disclosure refers to a method of producing an antibody, comprising culturing the host cell as disclosed herein under conditions suitable for production of the antibody. In some [embodimentexamples](#), the methods further comprise recovering the antibody from the host cell.

[0018] Further provided herein are compositions (*e.g.*, pharmaceutical compositions) comprising the antibody according to any one of the above [embodimentexamples](#) and a pharmaceutically acceptable carrier. In one aspect, the present disclosure refers to a pharmaceutical composition comprising the antibody as disclosed herein and a pharmaceutically acceptable carrier.

[0019] In further [aspectexamples](#), provided herein are methods for treating a disease or disorder in a subject, comprising administering to the subject an effective amount of the antibody or composition according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to use of the antibody as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for treating a disease or disorder in a subject. In some [embodimentexamples](#), administration of the antibody results in a reduction in the number of peripheral blood LGL or NK cells in the subject. In some [embodimentexamples](#), the disease or disorder is Felty's syndrome, and wherein administration of the antibody to the subject results in a reduction of one or more Felty's syndrome symptoms in the subject. In some [embodimentexamples](#), the disease or disorder is inclusion body myositis, and wherein administration of the antibody to the subject results in a reduction of one or more inclusion body myositis symptoms in the subject. In some [embodimentexamples](#), the disease or disorder is aggressive NK leukemia, and wherein administration of the antibody to the subject results in a reduction of one or more aggressive NK leukemia symptoms in the subject. In some [embodimentexamples](#), the disease or disorder is rheumatoid arthritis, and wherein administration of the antibody to the subject results in a reduction of one or more rheumatoid arthritis symptoms in the subject. In some [embodimentexamples](#), the disease or disorder is LGL leukemia, and wherein administration of the antibody to the subject results in a reduction of one or more LGL leukemia symptoms in the subject. In some [embodimentexamples](#), the disease or disorder is CLPD-NK, and wherein administration of the antibody to the subject results in a reduction of one or more CLPD-NK symptoms in the subject. In some [embodimentexamples](#), the disease or disorder is natural killer (NK) cell or T-cell lymphoma, and wherein administration of the antibody to the subject results in a reduction of one or more lymphoma symptoms in the subject. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (TCL), enteropathy-associated TCL, cutaneous TCL, anaplastic large cell lymphoma (ALK+), anaplastic large cell lymphoma (ALK-), peripheral TCL, angioimmunoblastic TCL, adult TCL, monomorphic epitheliotropic intestinal TCL, epidermotropic CD8+ cutaneous TCL, primary cutaneous gamma/delta TCL, or subcutaneous panniculitis TCL. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic TCL, or enteropathy-associated TCL. In some [embodimentexamples](#), the disease or disorder is microscopic colitis, and wherein administration of the antibody to the subject results in a reduction of one or more microscopic colitis symptoms in the subject.

[0020] In further [aspectexamples](#), provided herein are methods for reducing the number of peripheral blood LGL and/or NK cells in a subject, comprising administering to the subject an effective amount of the antibody or composition according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to use of the antibody as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for reducing the number of peripheral blood LGL and/or NK cells in a subject. In further [aspectexamples](#), provided herein are methods for inducing ADCC activity in a subject comprising administering to the subject an effective amount of the antibody or composition according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to use of the antibody as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for inducing ADCC activity in a subject. In further [aspectexamples](#), provided herein are methods for treating CLPD-NK in a human subject in need thereof comprising administering to the subject an effective amount of the antibody or composition according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to use of the antibody as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for treating CLPD-NK in a human subject in need thereof. In some [embodimentexamples](#), administration of the antibody results in an improvement of one or more CLPD-NK symptoms in the subject.

[0021] In further [aspectexamples](#), provided herein are methods of treating natural killer (NK) cell or T-cell lymphoma, comprising administering to a subject in need thereof an effective amount of the antibody

or

composition according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to use of the antibody as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for treating NK cell lymphoma in a subject in need thereof. In one aspect, the present disclosure refers to use of the antibody as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for treating T-cell lymphoma in a subject in need thereof. In some [embodimentexamples](#), the antibody does not bind to the same epitope on human CD94 as anti-CD94 antibody clones HP-3D9, HP-3B1, DX22, 131412, or 12K45. In some [embodimentexamples](#), the antibody binds to human CD94 with a greater affinity than anti-CD94 antibody clones HP-3D9, HP-3B1, DX22, 131412, and 12K45. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (TCL), enteropathy-associated TCL, cutaneous TCL, anaplastic large cell lymphoma (ALK+), anaplastic large cell lymphoma (ALK-), peripheral TCL, angioimmunoblastic TCL, or adult TCL. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic TCL, or enteropathy-associated TCL.

[0022] In further [aspectexamples](#), provided herein are methods of enhancing chimeric antigen receptor T cell (CAR-T) therapy in a human subject in need thereof, comprising administering to the subject an effective amount of the antibody or composition according to any one of the above [embodimentexamples](#) prior to administration of a CAR-T treatment to the subject. In one aspect, the present disclosure refers to use of the antibody as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for enhancing chimeric antigen receptor T cell (CAR-T) therapy in a human subject in need thereof, wherein an effective amount of the medicament is to be administered to the subject prior to administration of a CAR-T treatment to the subject. In some [embodimentexamples](#), administration of the antibody or composition results in depletion of NK cells in the subject prior to administration of the CAR-T treatment.

[0023] In further [aspectexamples](#), provided herein are methods of depleting CD8+ CD94+ T cells in a human subject in need thereof, comprising administering to the subject an effective amount of the antibody or composition according to any one of the above [embodimentexamples](#). In one aspect, the present disclosure refers to use of the antibody as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for depleting CD8+ CD94+ T cells in a human subject in need thereof. In some [embodimentexamples](#), administration of the antibody or composition results in depletion of CD8+ CD94+ T cells in the subject.

[0024] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the methods further comprise administering an IL-2 polypeptide to the subject.

[0025] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the subject is a human.

[0026] In further [aspectexamples](#), provided herein are the antibodies or compositions according to any one of the above [embodimentexamples](#) for use in: treating a disease or disorder in a subject, reducing the number of peripheral blood LGL and/or NK cells in a subject, treating CLPD-NK in a human subject in need thereof, treating natural killer (NK) cell or T-cell lymphoma, treating microscopic colitis in a subject, or enhancing CAR-T therapy in a subject in need thereof. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (TCL), enteropathy-associated TCL, cutaneous TCL, anaplastic large cell lymphoma (ALK+), anaplastic large cell lymphoma (ALK-), peripheral TCL, angioimmunoblastic TCL, adult TCL, monomorphic epitheliotropic intestinal TCL, epidermotropic CD8+ cutaneous TCL, primary cutaneous gamma/delta TCL, or subcutaneous panniculitis TCL. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic TCL, or enteropathy-associated TCL.

[0027] In further [aspectexamples](#), provided herein is the use of the antibodies or compositions according to any one of the above [embodimentexamples](#) for manufacture of a medicament, e.g., for use in: treating a disease or disorder in a subject, reducing the number of peripheral blood LGL and/or NK cells in a subject, treating

CLPD-NK in a human subject in need thereof, treating natural killer (NK) cell or T-cell lymphoma, treating microscopic colitis in a subject, or enhancing CAR-T therapy in a subject in need thereof. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (TCL), enteropathy-associated TCL, cutaneous TCL, anaplastic large cell lymphoma (ALK+), anaplastic large cell lymphoma (ALK-), peripheral TCL, angioimmunoblastic TCL, or adult TCL. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic TCL, or enteropathy-associated TCL.

[0028] In further [aspectexamples](#), provided herein are kits or articles of manufacture comprising the antibodies or compositions according to any one of the above [embodimentexamples](#). In some [embodimentexamples](#), the kits further comprise instructions for using the kits, *e.g.*, in treating a disease or disorder in a subject, reducing the number of peripheral blood LGL and/or NK cells in a subject, treating CLPD-NK in a human subject in need thereof, treating natural killer (NK) cell or T-cell lymphoma, treating microscopic colitis in a subject, or enhancing CAR-T therapy in a subject in need thereof. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (TCL), enteropathy-associated TCL, cutaneous TCL, anaplastic large cell lymphoma (ALK+), anaplastic large cell lymphoma (ALK-), peripheral TCL, angioimmunoblastic TCL, adult TCL, monomorphic epitheliotropic intestinal TCL, epidermotropic CD8+ cutaneous TCL, primary cutaneous gamma/delta TCL, or subcutaneous panniculitis TCL. In some [embodimentexamples](#), the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic TCL, or enteropathy-associated TCL.

[0029] In some [embodimentexamples](#), which may be combined with any of the preceding [embodimentexamples](#), an antibody of the disclosure comprises six CDRs from a single antibody listed in Table 1 (*e.g.*, antibody 18H3, 1M4, 1E4, ATX-122, ATX-123, ATX-124, ATX-125, ATX-126, ATX-127, ATX-128, ATX-129, or ATX-130). In some [embodimentexamples](#), which may be combined with any of the preceding [embodimentexamples](#), an antibody of the disclosure comprises a VH and VL domain from a single antibody listed in Table 2 (*e.g.*, antibody 18H3, 1M4, 1E4, ATX-122, ATX-123, ATX-124, ATX-125, ATX-126, ATX-127, ATX-128, ATX-129, or ATX-130).

[0030] All references cited herein, including patent applications and publications, are incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0032] **FIG. 1** shows the affinity of anti-CD94 antibody 18H3 for human primary natural killer (NK) cells as measured by flow cytometry. Peripheral blood mononuclear cells (PBMCs) of healthy donor HD-40 were used for antibody staining. 18H3 antibody was titrated from 100nM to 0.046nM in 1:3 dilutions and incubated with PBMCs. CD3 and CD56 antibodies were used to identify NK cells on the flow scatter.